ABSTRACT
We have analyzed the data of children's physical development who have celiac disease. The purpose of the study is to analyze the interrelations of celiac patients' anthropometric data with the age of diagnostics and the disease duration. 186 children with morphologically verified celiac disease at the age of from 9 months to 16 years were included. It was shown that the patients of pre-preschool age have the deficiency of body weight much more often than the growth delay. As they grow older and when the disease duration increases first of all we meet with stunting, as the result a number of children with normal growth at school age decreases to 23, 3 %, and the frequency of somatogenic nanism exceeds 50%. We have revealed the negative correlation between the symptoms duration of the disease and the deviation of growth data. We have confirmed the point of view that the presence of strong deviations of data of physical development which children have is the indication for the screening for celiac disease.
Subject(s)
Adolescent Development/physiology , Celiac Disease/physiopathology , Child Development/physiology , Adolescent , Age Factors , Anthropometry , Body Height/physiology , Body Mass Index , Body Weight/physiology , Celiac Disease/diagnosis , Child , Child, Preschool , Data Interpretation, Statistical , Female , Humans , Infant , MaleSubject(s)
Anti-Infective Agents/therapeutic use , Gastritis/drug therapy , Helicobacter Infections/drug therapy , Hydroxybenzoates/therapeutic use , Nitrofurans/therapeutic use , Peptic Ulcer/drug therapy , 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Adult , Anti-Infective Agents/administration & dosage , Chronic Disease , Clarithromycin/administration & dosage , Clarithromycin/therapeutic use , Drug Therapy, Combination , Female , Gastritis/microbiology , Helicobacter Infections/microbiology , Humans , Hydroxybenzoates/administration & dosage , Male , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Nitrofurans/administration & dosage , Pantoprazole , Peptic Ulcer/microbiology , Treatment OutcomeABSTRACT
Treatment of inflammatory diseases of the upper digestive tract, associated with Helicobacter pylori has recently greatly complicated by the presence of significant number of resistant strains of this microorganism to traditionally used drugs for eradication therapy. Average resistance to metronidazole and clarithromycin in Russia is about 30 and 25% respectively. The article presents the experience of treating patients with metronidazole resistant strains of H. pylori with using triple therapy, which included a drug used nitrofurans--nifuroxazide in suspension, proton pump inhibitors and clarithromycin.
